

Innovation Through Collaboration



NATIONAL INSTITUTES OF HEALTH Technology Transfer Center

- Serves as the United States' Medical Research Agency
- NIH's Impact Worldwide:
 - Driving economic growth and productivity
 - Improving health by promoting treatment and prevention
- 27 Institutes and Centers
 - Each with its own disease focus
- Connects NIH researchers and external partners
 - Exclusive/Non-exclusive licenses
 - Clinical Validation (Clinical Trial Agreements; CTAs)
 - Co-Development (Cooperative Research and Development Agreements; CRADAs)
 - Low-cost Tools/Reagents (Material Transfer Agreements; MTAs)



Licensing/Collaboration Agreements with the National Cancer Institute



- Address technology gaps
- Address knowledge gaps
- Enhance pipeline



\$ Boost product commercialization
\$ Expand addressable markets

NIH Value Proposition:

**Technical, Commercial,
Economic Development**

- >\$6B Product sales from licensed NIH IP (2020)
- Numerous advantages to working with us:
 - ✓ No up-front equity and 0-10% overhead rate
 - ✓ Won't take your IP
 - ✓ Validate your technology and/or test in humans
 - ✓ World-renowned researchers and resources
 - ✓ Prestige factor: Collaboration = higher company profile



Therapeutics



Diagnostics



Research Tools



Vaccines



Devices





Software

Partnering with NIH Offers Significant Commercialization Potential

Acquisition of Licensee

 **Kite** acquired by  **GILEAD** for US \$11B

 **MYST THERAPEUTICS** acquired by  **TURNSTONE BIOLOGICS** – terms undisclosed (2021)

Funding of Licensee

Rakuten Medical 2013 NCI License → \$13M Series A → \$55M Series B → \$284M Series C



2020 NCI License → \$1.8M Seed Closing

Collaborators and Licensees

Organization	Product	2020 Worldwide Sales
 MERCK	 GARDASIL	US \$3.6B
 Janssen	 PREZISTA[®] (darunavir) tablets	US \$2.2B
 abbvie sobi AstraZeneca	 SYNAGIS[®] PALIVIZUMAB	US \$1.6B
 Takeda	 VELCADE[®] (bortezomib)	US \$1.3B
 Eisai	 Halaven[®] (eribulin mesylate) Injection 0.5 mg/ml	US \$595M

NIH Technology Portfolio

- **Assets available for licensing/collaboration:**
 - Small molecules
 - Biologics
 - Devices
 - Diagnostics
 - Vaccines
 - Wearables and Digital health
 - Software
 - Research tools (cells, mice, etc.)
- **Pre-clinical and clinical stage technologies**

Website

www.ott.nih.gov

- Listserv distributions of new opportunities
- Technologies available for licensing and co-development

General Inquiries

Please reach out to:
NCITechTransfer@mail.nih.gov

Social Media



www.linkedin.com/company/intramural-research-program-irp/



@NIHOTT